Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat and Rasburicase on Endothelial Function and Oxidative Stress
NCT03395977Completed
- Sponsor
- Erasmus Hospital
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules, Replacement Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of febuxostat and rasburicase in endothelial dysfunction, hypertension (HTN) and oxidative stress (4 arms), sponsored by Erasmus Hospital. Primary endpoint: Cutaneous perfusion by Laser Doppler at 24 hours. Started Jan 2018; status: completed.
02
Drugs
febuxostatrasburicase
03
Conditions
endothelial dysfunctionhypertension (HTN)oxidative stress
Beyond the preview
Go deeper on NCT03395977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395977.